Table 1 Demographics and clinical characteristics of the study participants

N

580

149

212

134

58

12

15

Age (years)

69.8 ± 11.0

69.6 ± 7.7

70.0 ± 8.3

70.2 ± 11.0

77.4 ± 8.5^*,†,$

76.8 ± 6.9

32.5 ± 3.9^*,†,$

Female sex

362 (62.4)

98 (65.8)

119 (56.1)

90 (67.7)^†

44 (74.6)^†

6 (50.0)

6 (40.0)^{*,$,^}

APOE4 carrier

214 (36.9)

38 (25.5)

85 (40.1)^*

75 (56.4)^*,†

12 (20.3)^†,$

1 (8.3)^†,$

3 (20.0)^$

PET positivity^a

280/578^b (48.4)

17 (11.4)

119 (56.1)^*

113/133 (85.0)^*,†

22 (37.9)^*,†,$

9/11 (81.8)^{*,^}

0 (0.0)^{†,$,^,#}

MMSE

24 ± 5.4

27.8 ± 2.5

22.5 ± 3.3^*

18.5 ± 5.3^*,†

22 ± 5.4^*,†,$

21 ± 7.3^*,$

N/A

Plasma Aβ42

56.9 ± 16.2 (n = 577)

60 ± 14.4

56.1 ± 16.3

51.7 ± 15.5^*

64.8 ± 18.2^†,$

55.7 ± 20.3

52.2±5^{^}

Plasma Aβ40

217 ± 58.2 (n = 572)

215.8 ± 52.5

216 ± 55

210.8 ± 60.3

241.7 ± 68.1^*,†,$

237.1 ± 86.4

184.4 ± 15.6^{^}

Plasma Aβ42/Aβ40

0.27 ± 0.06 (n = 572)

0.28 ± 0.05

0.27 ± 0.05^*

0.26 ± 0.08^*

0.28 ± 0.07

0.24 ± 0.03

0.28 ± 0.03